Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $25.1400 (-1.22%) ($24.8300 - $25.6300) on Wed. Jul. 11, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.45% (three month average) | RSI | 43 | Latest Price | $25.1400(-1.22%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(22%) IBB(20%) XOP(17%) IWM(16%) IWO(16%) | Factors Impacting ADMS price | ADMS will decline at least -1.225% in a week (0% probabilities). VIXM(-10%) UNG(-10%) BNDX(-9%) UUP(-8%) VXX(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.225% (StdDev 2.45%) | Hourly BBV | 0 () | Intraday Trend | -0.3% | | | |
|
Resistance Level | $25.6 | 5 Day Moving Average | $25.46(-1.26%) | 10 Day Moving Average | $25.39(-0.98%) | 20 Day Moving Average | $25.6(-1.8%) | To recent high | -23% | To recent low | 4.3% | Market Cap | $711m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |